Efficacy of Postoperative Immunosuppression After Keratoplasty in Herpetic Keratitis

Purpose: Recurrence of herpetic keratitis and immune reactions is the major cause of graft failures after penetrating keratoplasty as a consequence of herpes simplex keratitis. No treatment regimen is yet considered a standard of care. This retrospective study analyzes the effectiveness of combined systemic acyclovir and immunosuppressive therapy with cyclosporine A (CSA) or mycophenolate mofetil (MMF) after high-risk keratoplasty in herpetic keratitis. Methods: A total of 87 high-risk keratoplasties treated with postoperative combined systemic acyclovir and immunosuppressive therapy with CSA or MMF were analyzed retrospectively according to the therapeutic regimen, the degree of preoperative corneal vascularization, and tissue matching of the graft. Endpoints included immunological graft rejection, recurrence of the herpetic keratitis, graft failure, and visual acuity. Results: There was an overall trend toward an improvement of visual acuity. Graft failure occurred in 13.1%, in all cases after termination of immunosuppression with MMF or CSA. In 4 of 11 cases, immune reactions caused graft failure. Patients with 3 to 4 quadrants of corneal vascularization showed significantly higher rates of graft rejection than patients with 1 to 2 quadrants vascularized or avascular corneas. Herpetic recurrence occurred in 31.8% and caused 18.2% of graft failure. In 7 of 23 cases, graft rejection was induced by herpetic recurrence. Conclusions: Graft survival rate and functional outcome after postoperative antiviral and immunosuppressive treatment in cases of penetrating keratoplasties after herpetic keratitis are comparable with results of normal-risk keratoplasties, despite existing high risks for immune rejections or herpetic recurrences.

[1]  Roni M. Shtein,et al.  Herpes Simplex Virus Keratitis: Histopathologic Neovascularization and Corneal Allograft Failure , 2009, Cornea.

[2]  P. Mulder,et al.  Five-Year Follow-Up on the Effect of Oral Acyclovir After Penetrating Keratoplasty for Herpetic Keratitis , 2009, Cornea.

[3]  Roni M. Shtein,et al.  Herpes simplex virus keratitis: histopathologic inflammation and corneal allograft rejection. , 2009, Ophthalmology.

[4]  P. Charukamnoetkanok,et al.  Management of herpes simplex virus stromal keratitis: an evidence-based review. , 2009, Survey of ophthalmology.

[5]  Soo-Hyun Park,et al.  Effect of Topical Cyclosporin A on Herpetic Stromal Keratitis in a Mouse Model , 2008, Cornea.

[6]  T. Foster,et al.  Ocular HSV-1 Latency, Reactivation and Recurrent Disease , 2008, Seminars in ophthalmology.

[7]  D. Musch,et al.  Effect of Prophylactic Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis , 2007, Cornea.

[8]  F. Hoffmann,et al.  [Typing for HLA matching. Advantages for keratoplasty]. , 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[9]  F. Hoffmann,et al.  Typisierung beim HLA-Matching , 2007, Der Ophthalmologe.

[10]  B. Kirchhof,et al.  Autologous translocation of the choroid and retinal pigment epithelium in age-related macular degeneration. , 2006, American journal of ophthalmology.

[11]  B. Rouse,et al.  Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Seitz,et al.  Systemic mycophenolate mofetil avoids immune reactions in penetrating high‐risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study * , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  T. Reinhard,et al.  Penetrating limbo-keratoplasty for granular and lattice corneal dystrophy: survival of donor limbal stem cells and intermediate-term clinical results. , 2004, Ophthalmology.

[14]  J. Hill.  The use of systemic cyclosporin a in human corneal transplantation: a preliminary report , 1986, Documenta Ophthalmologica.

[15]  C. Foster,et al.  Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis , 2004, Documenta Ophthalmologica.

[16]  T. Reinhard,et al.  Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  M. Böhnke,et al.  The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin , 2002, The British journal of ophthalmology.

[18]  D. Gartry,et al.  Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study , 2001, The British journal of ophthalmology.

[19]  B. Rouse,et al.  Bystander Activation Involving T Lymphocytes in Herpetic Stromal Keratitis1 , 2001, The Journal of Immunology.

[20]  E. Godehardt,et al.  Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  T. Reinhard,et al.  Hochaktive antivirale und immunsuppressive Kombinationstherapie mit Acyclovir und Mycophenolatmofetil nach Keratoplastik bei herpetischer Grunderkrankung , 2001 .

[22]  T. Liesegang.  Herpes Simplex Virus Epidemiology and Ocular Importance , 2001, Cornea.

[23]  M. Araie,et al.  Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. , 1999, Japanese journal of ophthalmology.

[24]  T. Reinhard,et al.  [Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease]. , 2001, Klinische Monatsblätter für Augenheilkunde.

[25]  H. Völker‐Dieben,et al.  BENEFICIAL EFFECT OF HLA-DR MATCHING ON THE SURVIVAL OF CORNEAL ALLOGRAFTS1 , 2000, Transplantation.

[26]  E. Godehardt,et al.  Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial , 1999, The British journal of ophthalmology.

[27]  T. Reinhard,et al.  [Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study]. , 1999, Klinische Monatsblätter für Augenheilkunde.

[28]  E. Cohen,et al.  Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. , 1999, Archives of ophthalmology.

[29]  Y. Akova,et al.  Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. , 1999, Ocular immunology and inflammation.

[30]  E. De Clercq,et al.  Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. , 1998, Antiviral research.

[31]  B. Rouse,et al.  Virus-induced immunoinflammatory lesions in the absence of viral antigen recognition. , 1998, Journal of immunology.

[32]  B. Rouse,et al.  Immunopathology of herpetic stromal keratitis: discordance in CD4+ T cell function between euthymic host and reconstituted SCID recipients. , 1998, Journal of immunology.

[33]  T. Reinhard,et al.  [Postoperative complications of penetrating keratoplasty in herpes infected eyes. Differential diagnosis, therapy and prognostic significance]. , 1997, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[34]  T. Reinhard,et al.  Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhöhtem Risiko für Immunreaktionen als einzigem erhöhten Risikofaktor , 1997, Der Ophthalmologe.

[35]  E. Godehardt,et al.  [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. , 1997, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[36]  Hill Jc.  The relative importance of risk factors used to define high-risk keratoplasty. , 1996 .

[37]  J. Hill.  The relative importance of risk factors used to define high-risk keratoplasty. , 1996, German journal of ophthalmology.

[38]  J. C. Hill,et al.  Systemic cyclosporine in high-risk keratoplasty: Long-term results , 1995, Eye.

[39]  J. C. Hill,et al.  Immunosuppression in corneal transplantation , 1995, Eye.

[40]  A. Ivey,et al.  Corticosteroids in Corneal Graft Rejection: Double Versus Single Pulse Therapy , 1994, Cornea.

[41]  N. Barney,et al.  A Prospective Randomized Trial of Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis , 1994, Cornea.

[42]  D. Musch,et al.  Antiviral therapy after penetrating keratoplasty for herpes simplex keratitis. , 1994, Archives of ophthalmology.

[43]  J. Hill,et al.  Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. , 1994, Ophthalmology.

[44]  D. Pavan-Langston,et al.  Herpetic Keratitis: Persistence of Viral Particles Despite Topical and Systemic Antiviral Therapy: Report of Two Cases and Review of the Literature , 1993 .

[45]  L. Ficker,et al.  The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. , 1989, Ophthalmology.

[46]  H. Thiel,et al.  The use of cyclosporine in high-risk keratoplasty. , 1989, American journal of ophthalmology.

[47]  R. D. Stulting,et al.  Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. , 1987, Ophthalmology.